PHACS – Pediatric HIV/AIDS Cohort Study
The National Institutes of Child Health and Human Development (NICHD) and eight other NIH Institutes established the Pediatric HIV/AIDS Cohort Study (PHACS) in 2006 to address two critical pediatric HIV research questions: 1) the long-term safety of fetal and infant exposure to prophylactic antiretroviral (ART) chemotherapy; and 2) the effects of perinatally acquired HIV infection in adolescents and young adults. The research efforts of PHACS evaluate the impact of HIV and ART on physical and mental development, sexual maturation, pubertal development, socialization, and transition to adulthood, and a drug toxicity surveillance system among perinatally HIV exposed and uninfected children evaluates the long-term effects of their perinatal ART exposure.
The PHACS Data and Operations Center (DOC) is based at Harvard School of Public Health and is led by Dr. George Seage. The DOC provides operations, design, methodologic, and analytic expertise and support to the development of the PHACS protocols. It also trains and monitors clinical sites in proper procedures for PHACS research, supports an active study-wide Community Advisory Board (CAB), and leads health education and communication efforts for PHACS.
Harvard School of Public Health launched a new PHACS website in April 2014 that describes the study structure, research, participating sites, press coverage, and community outreach efforts. For the most up-to-date information about PHACS, please visit our website at https://phacsstudy.org.